DREAMM15

A Phase 2, Multicenter, Open Label, Non-randomized Study to Evaluate the Efficacy and Safety of Extended Dosing of Belantamab Mafodotin in Different Combinations With Standard of Care Regimens in Participants With Relapsed-refractory Multiple Myeloma (DREAMM-15)

Near Add Your Location

Sorting 5 by

UCLA Torrance Oncology
UCLA Health
Torrance, CA
  • Accepting patients
American Oncology Partners of Maryland (Bethesda)
The Center for Cancer & Blood Disorders - Bethesda
Bethesda, MD
  • Accepting patients
  • Show Principal Investigator
Medical Center of Central Georgia
Macon, GA
  • Accepting patients
  • Show Principal Investigator
Oncology Hematology Associates (OHA)
American Oncology
Springfield, MO
  • Accepting patients
  • Show Principal Investigator

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print Report

Print this trial to share with your doctor.

(888) 828-2206

We can help answer any questions and connect you (or your patient) with the study team.

Schedule Call

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.